Latham & Watkins advises Revolution Medicines on the deal, and Goodwin Procter advises EQRx. Revolution Medicines, Inc. (Nasdaq: RVMD) and EQRx, Inc. (Nasdaq: EQRX) announced a definitive agreement...
You must be a Standard 1 Year member to access this content.
Goodwin Procter advised Wellth, Inc. on the deal. Wellth, Inc. announced its $20 million Series B financing round led by SignalFire. Headquartered in Los Angeles, California,...
You must be a Standard 1 Year member to access this content.
Goodwin Procter advised BridgeBio Pharma on the offering, and Latham & Watkins advised the underwriters involved. BridgeBio Pharma, Inc. announced the pricing on March 7, 2023 of...
You must be a Standard 1 Year member to access this content.
Goodwin Procter advised FogPharma® on the deal. FogPharma® announced its $178 Million Series D financing. FogPharma is a biopharmaceutical company pioneering a new class of precision...
You must be a Standard 1 Year member to access this content.
